Stock listing
OTC:ACUR Acura Pharmaceuticals, Inc. Stock
Follow Acura Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · OTC:ACUR
$0.0003 USD 0.0000 (0.0%)
Close on Nov 17, 2026
- Day range
- $0.0003 – $0.0003 USDNov 17, 2026
- Volume
- 200 sharesNov 17, 2026
- Market cap
- $19,801 USDAt the close on Nov 17, 2026 · price × 66.00M shares outstanding
- 52-week range
- $0.0001 – $0.0009 USDLowest and highest trades, Nov 18, 2025 – Nov 17, 2026
- Traded on an average day
- $0 USDMedian day 0 shares · 43 days with no trades · last 3 months, Aug 17, 2026 – Nov 17, 2026

Daily closes
Last 3 months, Aug 17, 2026 – Nov 17, 2026 · OTC:ACUR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 200 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 6,184 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 0 | |
| $0.0003 | 0.0000 | 0.0% | $0.0003 | $0.0003 | $0.0003 | 0 | |
| $0.0003 | +0.0001 | +50.0% | $0.0003 | $0.0003 | $0.0003 | 200 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | 0.0000 | 0.0% | $0.0002 | $0.0002 | $0.0002 | 0 | |
| $0.0002 | +0.0001 | +100.0% | $0.0002 | $0.0002 | $0.0002 | 2,395 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 35,044 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,113 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 500 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 200 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 34,348 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 120 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 300 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 1,050 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 2,221 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0004 | $0.0004 | $0.0001 | 400 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 265 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 400 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 112 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 12,900 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 | |
| $0.0001 | 0.0000 | 0.0% | $0.0001 | $0.0001 | $0.0001 | 0 |
Splits
2 splits since 2007 · OTC:ACUR · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- OTC:ACUR
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Acura Pharmaceuticals, Inc. on 6ix
- Decks
- 11 decks · latest Sep 11, 2017
Valuation
price Nov 17, 2026
- Enterprise value
- No statements on 6ix yet
- P/E
- No statements on 6ix yet
- EV/sales
- No statements on 6ix yet
- EV/EBITDA
- No statements on 6ix yet
- Price/book
- No statements on 6ix yet
- Gross margin
- No statements on 6ix yet
- Operating margin
- No statements on 6ix yet
- Net margin
- No statements on 6ix yet
- Debt to equity
- No statements on 6ix yet
- Beta vs S&P 500
- -0.56
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2024 | Nov 18, 2024 | 0.0% |
| Quarter to Jun 30, 2024 | Aug 20, 2024 | +2.8% |
| Quarter to Mar 31, 2024 | May 21, 2024 | +66.7% |
| Quarter to Dec 31, 2023 | Feb 28, 2024 | +220.0% |
| Quarter to Sep 30, 2023 | Nov 13, 2023 | |
| Quarter to Jun 30, 2023 | Aug 7, 2023 · After close | 0.0% |
| Quarter to Mar 31, 2023 | Jun 30, 2023 · After close | |
| Quarter to Dec 31, 2022 | Mar 3, 2023 · After close | |
| Quarter to Sep 30, 2022 | Nov 14, 2022 | |
| Quarter to Jun 30, 2022 | Aug 15, 2022 |
All 16 quarters
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2022 | May 2, 2022 | |
| Q4 2021 | Mar 31, 2022 | |
| Q3 2021 | Nov 15, 2021 | |
| Q2 2021 | Aug 16, 2021 | |
| Q1 2021 | May 17, 2021 | |
| Q4 2020 | Mar 31, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Rodman & Renshaw Conference 2017 | Conference | 24 slides | Sep 11, 2017 |
| Technical Presentation (June 2017) | Technical | 11 slides | Jun 28, 2017 |
| Technical Presentation (July 2016) | Technical | 14 slides | Jul 13, 2016 |
| Technical Presentation (June 2016) | Technical | 12 slides | Jun 8, 2016 |
| Technical Presentation (April 2016) | Technical | 13 slides | Apr 14, 2016 |
| Investor Presentation (March 2016) | Investor deck | 19 slides | Mar 11, 2016 |
| Investor Presentation (September 2015) | Investor deck | 23 slides | Sep 28, 2015 |
| Roth Capital Conference March 2014 | Conference | 27 slides | Mar 10, 2014 |
| Cowen Health Care Conference 2013 | Conference | 26 slides | Mar 4, 2013 |
| Stifel Nicolaus Conference 2012 | Conference | 20 slides | Sep 4, 2012 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Needham & Company Healthcare Conference 2012 | Conference | 24 slides | Apr 2, 2012 |
Financials
Annual, in USD
Income statement
| Line | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.56M | 3.57M | 2.66M | 410.0K | 2.97M | 4.46M | 8.59M | 751.0K | 123.0K | |
| Cost of revenue | 0 | 128.0K | 477.0K | 986.0K | 5.01M | 364.0K | 9.61M | |||
| Gross profit | 3.57M | 2.66M | 410.0K | 2.84M | 3.99M | 7.60M | -4.26M | -241.0K | ||
| Research and development | 1.52M | 1.78M | 1.50M | 1.76M | 3.72M | 4.03M | 2.61M | 4.58M | 4.92M | 3.73M |
| Selling, general and administrative | 1.25M | 2.55M | 1.88M | 2.57M | 4.34M | 6.52M | 8.99M | 7.94M | 8.93M | 6.01M |
| Operating income | -1.21M | -758.0K | -725.0K | -3.92M | -5.22M | -6.56M | -4.00M | -12.2M | -14.1M | -9.74M |
| Depreciation and amortization | 90.0K | 125.0K | 339.0K | 367.0K | 393.0K | 490.0K | 518.0K | 274.0K | 134.0K | 131.0K |
| EBITDA | -1.12M | -633.0K | -386.0K | -3.55M | -4.83M | -6.07M | -3.48M | -11.9M | -14.0M | -9.61M |
| Interest expense | 200.0K | 450.0K | 462.0K | 395.0K | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | -879.0K | -1.21M | -3.77M | -3.84M | -5.82M | -7.39M | -4.99M | -13.2M | -13.9M | -9.67M |
| Income tax | -135.0K | 0 | 0 | 0 | 0 | |||||
| Net income | -879.0K | -1.21M | -3.77M | -3.84M | -5.68M | -7.39M | -4.99M | -13.2M | -13.9M | -9.67M |
| Earnings per share, basic | -0.01 | -0.06 | -0.18 | -0.18 | -0.27 | -0.62 | -0.42 | -0.29 |
Balance sheet
| Line | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 65.0K | 413.0K | 862.0K | 91.0K | 2.22M | 5.18M | 2.48M | 774.0K | 12.3M | 7.48M |
| Short-term investments | 0 | 10.8M | 11.3M | 13.7M | 19.9M | |||||
| Receivables | 158.0K | 627.0K | 34.0K | 67.0K | 71.0K | 23.0K | 295.0K | 142.0K | 500.0K | 43.0K |
| Inventory | 0 | 309.0K | 276.0K | 304.0K | 251.0K | 219.0K | ||||
| Current assets | 372.0K | 1.18M | 1.18M | 461.0K | 2.57M | 5.91M | 14.1M | 13.2M | 27.5M | 28.0M |
| Property, plant and equipment | 484.0K | 540.0K | 606.0K | 679.0K | 867.0K | 1.01M | 957.0K | 941.0K | 1.05M | |
| Total assets | 860.0K | 1.74M | 2.56M | 2.15M | 4.60M | 8.21M | 17.0M | 16.0M | 28.6M | 29.1M |
| Accounts payable | 192.0K | 662.0K | 822.0K | 1.20M | 1.64M | 780.0K | 674.0K | 217.0K | 815.0K | 1.41M |
| Current liabilities | 515.0K | 7.52M | 1.07M | 1.44M | 4.63M | 3.49M | 3.24M | 2.99M | 1.11M | 1.42M |
| Long-term debt | 150.0K | 105.0K | 6.00M | 4.22M | 2.98M | 5.43M | 7.80M | 9.60M | ||
| Total liabilities | 682.0K | 7.63M | 7.30M | 5.77M | 4.63M | 7.03M | 9.06M | 11.0M | 10.7M | 1.42M |
| Shareholders' equity | 178.0K | -5.89M | -4.74M | -3.62M | -27.0K | 1.18M | 7.90M | 5.05M | 17.9M | 27.6M |
| Shares outstanding | 65.1M | 21.6M | 21.3M | 21.0M | 20.8M | 11.8M | 11.8M | 48.3M |
Cash flow
| Line | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -742.0K | -719.0K | -618.0K | -3.91M | -4.51M | -5.56M | -3.69M | -11.0M | -13.7M | -7.04M |
| Capital spending | 0 | 0 | 0 | 0 | 0 | -75.0K | -214.0K | -135.0K | -23.0K | -147.0K |
| Free cash flow | -742.0K | -719.0K | -618.0K | -3.91M | -4.51M | -5.64M | -3.90M | -11.2M | -13.7M | -7.18M |
| Cash from investing | 309.0K | 10.8M | 108.0K | -2.00K | 6.25M | -20.1M | ||||
| Cash from financing | 394.0K | 270.0K | 1.39M | 1.78M | 1.24M | -2.54M | 5.29M | -520.0K | 12.3M | -1.04M |
| Share buybacks | 4.00M | 1.00K | -610.0K | 9.00K | 10.0K | 10.0K | ||||
| Change in cash | -348.0K | -449.0K | 771.0K | -2.13M | -2.96M | 2.70M | 1.71M | -11.6M | 4.86M | -28.2M |
Cap table
Built by 6ix from Acura Pharmaceuticals, Inc.’s releases
- Common shares
- 66,001,783
- Fully diluted
- 66,001,783
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 66,001,783 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 66,001,783 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard J Markham Other companies: Vaxart, Inc. (Director · Feb 13, 2018 – Jun 12, 2019 · Past); CoLucid Pharmaceuticals Inc (Director · May 5, 2015 – May 11, 2015 · Past); NephroGenex Inc (Director · Feb 10, 2014 – Apr 30, 2015 · Past) | Director · Jan 2, 2009 – Jan 2, 2013 · Past |
| Albert W Brzeczko | See Remarks · Feb 9, 2009 – Nov 20, 2023 · Past |
| Bruce F Wesson | Director · Jan 2, 2024 – Jan 2, 2024 · Past |
| George K Ross | Director · Since at least Jan 2, 2009 |
| Immanuel Thangaraj | Director · Since at least Jan 2, 2026 |
| James F Emigh | VP, Corporate Development · Jan 4, 2021 – Feb 24, 2021 · Past |
| J Bradley Rivet | VP Marketing · Oct 3, 2011 – Dec 8, 2016 · Past |
| Peter A Clemens | Senior VP & CFO · Dec 8, 2016 – Nov 20, 2023 · Past |
| Robert B Jones | President & CEO · Dec 8, 2016 – Nov 20, 2023 · Past |
| William G Skelly | Director · Since at least Nov 14, 2008 |
Log in to ask 6ix AI your own questions about Acura Pharmaceuticals, Inc.